-
Digoxin Workflows for Cardiac and HIF-1α Research
2026-08-23
Digoxin is a versatile Na+/K+ ATPase pump inhibitor for connecting cardiac physiology, viral-cell assays, and hypoxia-driven inflammation research. This workflow-focused guide shows how to prepare, dose, control, and troubleshoot Digoxin experiments while translating a new thyroid eye disease finding into practical assay design.
-
AIBP-LRP2 Restricts CXCR4+ Collateral Growth
2026-08-22
The reference study identifies an AIBP-LRP2–HDL–miR-223 pathway that limits expansion of CXCR4+ stemlike capillary endothelial cells during ischemic remodeling. Its two-phase model links capillary expansion to later arterialization and suggests that disrupting this axis could improve collateral circulation in peripheral artery disease.
-
Diethylmaleate in Redox and GST Research
2026-08-21
Diethylmaleate is a glutathione-depleting redox research reagent used to study oxidative stress, ROS signaling, GST function, and apoptosis. In a 2024 insect toxicology study, diethyl maleate inhibited GST activity by 64.05% and increased lambda-cyhalothrin sensitivity 7.91-fold under the reported assay conditions.
-
Rucaparib DNA Repair Workflows
2026-08-20
Rucaparib (AG-014699) connects PARP1 inhibition with measurable DNA-damage and radiation-response assays. This guide translates spliceosome–DNA-repair findings in hepatocellular carcinoma into practical workflows for cancer research, while distinguishing validated evidence from testable extensions.
-
Olsalazine Sodium: Research Workflow Guide
2026-08-20
Olsalazine Sodium combines water-compatible handling with a defined LTB4 chemotaxis readout for inflammation and cancer research. This guide translates its mesalamine dimer chemistry into reproducible cell, rodent, and exploratory xenobiotic-transport workflows while highlighting solubility, dosing, and interpretation safeguards.
-
JNJ-26854165: Practical p53 Assay Workflows
2026-08-19
Build more informative cancer assays with JNJ-26854165 (Serdemetan), an HDM2 antagonist suited to p53-pathway, proliferation, apoptosis, migration, and radiation-response studies. The key advantage is pairing growth-inhibition measurements with time-resolved cell-death assays rather than treating viability as a single endpoint.
-
AG-221 (Enasidenib) Workflow for IDH2 AML
2026-08-19
Build a reproducible IDH2-mutant AML workflow around AG-221 (Enasidenib), linking 2-hydroxyglutarate reduction to metabolic and differentiation readouts. The guide also shows how to use CD44-centered assays to investigate response, resistance, and combination strategies.
-
Amyloid β-Peptide (1-42) in Translational AD Research
2026-08-18
Aβ42 is more than an amyloid challenge reagent: it is a translational stress test linking neuronal toxicity, ion-channel dysfunction, redox imbalance, and ferroptosis. This article outlines how to use Amyloid β-Peptide (1-42) (human) to build mechanistically anchored assays, interpret rescue data, and connect cellular findings with emerging Alzheimer’s disease biology.
-
G-15 as a GPR30 Causality Tool in Osteoblasts
2026-08-18
G-15 is a G protein-coupled estrogen receptor antagonist for dissecting GPR30 signaling in osteoblast models. This article translates recent osteoporosis findings into a rigorous assay strategy linking receptor antagonism with calcium, PI3K/Akt, and osteogenic readouts.
-
RNA Pol II Loss Activates Apoptosis Beyond Transcription
2026-08-17
Harper and colleagues show that RNA Pol II inhibition kills cells through an active apoptotic program triggered by depletion of hypophosphorylated RNA Pol IIA, rather than through passive loss of transcriptional output. Their functional-genomic framework defines the Pol II degradation-dependent apoptotic response and provides a basis for interpreting how diverse anticancer compounds can converge on mitochondrial cell-death signaling.
-
iPSC Prescreening for Ultrarare Disease Trials
2026-08-17
Sequiera et al. developed a patient-specific iPSC platform to evaluate drug safety and efficacy before clinical trial participation in an ultrarare Leigh-like syndrome caused by poorly characterized ECHS1 variants. The study shows how matched cellular models can replace some trial-and-error treatment decisions with functional, individualized evidence, although the approach remains a single-patient proof of concept.
-
Tp47–PKM2 Drives Macrophage Inflammatory Senescence
2026-08-16
The reference study identifies a mechanistic link between the Treponema pallidum protein Tp47, PKM2-dependent metabolic reprogramming, and inflammatory senescence in macrophages. Its findings position glycolytic activity, lactate signaling, and EIF2AK2 phosphorylation as interconnected features of pathogen-associated senescence, while also highlighting the need to combine SA-β-Gal measurements with inflammatory and metabolic readouts.
-
TP53 Shapes Calicheamicin ADC Response in Leukemia
2026-08-15
This study combines genome-wide CRISPR/Cas9 screening with genetic and pharmacological validation to identify TP53, ATM, and MDM2 as important modulators of calicheamicin sensitivity in acute leukemia. The findings clarify why gemtuzumab ozogamicin and inotuzumab ozogamicin may show variable activity and provide a rationale for testing selected DNA damage response combinations, while also showing that PARP inhibition was not a broadly effective sensitization strategy in this model.
-
Cy3 TSA Fluorescence System Kit for Cardiac Research
2026-08-14
Learn how the Cy3 TSA Fluorescence System Kit can resolve low-abundance inflammatory and endothelial signals in doxorubicin cardiotoxicity models. This practical guide connects tyramide signal amplification with cardiac tissue imaging, multiplex assay design, workflow controls, and troubleshooting.
-
Bestatin hydrochloride: Reliable Cell Assays
2026-08-14
Learn how Bestatin hydrochloride, SKU A8621, can support better-controlled viability, proliferation, cytotoxicity, and angiogenesis experiments. This scenario-based guide emphasizes mechanism-aware interpretation, solvent controls, storage, protocol optimization, and practical reagent selection.